Reumatologia Clinica最新文献

{"title":"Junta Directiva de la SER, Comité de Organización de Congresos, Comité Científico del Congreso y Comité Organizador Local del Congreso","authors":"","doi":"10.1016/S1699-258X(25)00143-3","DOIUrl":"10.1016/S1699-258X(25)00143-3","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 ","pages":"Pages I-II"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144702255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pósteres: P1-P170","authors":"","doi":"10.1016/S1699-258X(25)00146-9","DOIUrl":"10.1016/S1699-258X(25)00146-9","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 ","pages":"Pages S146-S309"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144702258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pósteres: P171-P318","authors":"","doi":"10.1016/S1699-258X(25)00147-0","DOIUrl":"10.1016/S1699-258X(25)00147-0","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 ","pages":"Pages S310-S455"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144702259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estudio del impacto de la inclusión de la valoración global del dolor y la capacidad funcional en la definición de remisión y su mantenimiento en la artritis reumatoide. Objetivos y metodología","authors":"Alejandro Balsa ,&nbsp;Daniel Seoane-Mato ,&nbsp;Marta Domínguez-Álvaro ,&nbsp;Mercedes Alperi ,&nbsp;Virginia Ruiz-Esquide ,&nbsp;Javier Bachiller-Corral ,&nbsp;Federico Díaz-González ,&nbsp;en representación del Grupo del estudio Remisión-AR","doi":"10.1016/j.reuma.2025.501895","DOIUrl":"10.1016/j.reuma.2025.501895","url":null,"abstract":"<div><h3>Background and objective</h3><div>The SUMAR project established a definition for remission that includes the patient's perspective (global assessment of pain and HAQ) in the definition of remission in rheumatoid arthritis (RA). This new definition needs to be assessed on clinical practice. The main objective of the RA-Remission study is to estimate the proportion of patients in sustained remission according to SUMAR definition through 2-year follow-up, among patients in SUMAR remission at baseline. This manuscript describes the objectives and methodology of the study.</div></div><div><h3>Materials and methods</h3><div>This is a longitudinal, prospective, observational and multicentre study, involving 10 centres. Patients with RA who have achieved clinical remission in accordance to their attending rheumatologist clinical judgement within the last 6 months will be included. Follow-up visits will take place at 3, 6, 12, 12, 18 and 24 months. Ultrasound assessment of the power Doppler (PD) signal for 30 joints and 6 tendon regions will be performed at each participating centre by an expert blinded to all other study findings. Definitions of remission according to SUMAR, PD and activity indices will be used. Sustained remission will be considered for each of the definitions when the patient in remission at the baseline visit maintains it during all follow-up visits. To estimate the proportion of patients maintaining remission at two years with an accuracy of at least 6%, 180 patients will need to be recruited.</div></div><div><h3>Discussion and conclusions</h3><div>The main strength of the design is the use of ultrasound assessment as the gold standard for assessing inflammatory activity.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501895"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular inflammatory manifestations in patients with rheumatoid arthritis","authors":"Raul E. Ruiz-Lozano ,&nbsp;Luis Arnaldo Prida-Espaillat ,&nbsp;Reinaldo A. Moll-Auais ,&nbsp;Eugenia M. Ramos-Dávila ,&nbsp;Manuel E. Quiroga-Garza ,&nbsp;Aaron Zhao ,&nbsp;Ali Khodor ,&nbsp;Amr Almobayed ,&nbsp;David Vega-Morales ,&nbsp;Alejandro Rodriguez-Garcia","doi":"10.1016/j.reuma.2025.501891","DOIUrl":"10.1016/j.reuma.2025.501891","url":null,"abstract":"<div><h3>Purpose</h3><div>This review emphasizes the significance of clinical findings, pathogenic mechanisms, diagnosis, management, and complications related to the ocular manifestations of rheumatoid arthritis, underscoring the need for interdisciplinary collaboration between rheumatologists and ophthalmologists.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted using PubMed, Embase, Web of Science, and Google Scholar for all English-language articles published from inception to July 2024. The following search string was utilized: (“rheumatoid arthritis”) AND (“dry eye disease” OR “dry eye” OR “episcleritis” OR “scleritis” OR “peripheral ulcerative keratitis” OR “central corneal ulcer*” OR “paracentral corneal ulcer*” OR “ocular manifestations” OR “ocular involvement”). Letters to the editor, editorials, short communications, case reports, case series, review articles, and original articles were reviewed, along with relevant references from those publications.</div></div><div><h3>Results</h3><div>The most common ocular manifestations in patients with rheumatoid arthritis include keratoconjunctivitis sicca (dry eye disease), episcleritis, scleritis, peripheral ulcerative keratitis, and central and paracentral corneal ulceration. Ocular involvement can be the initial presentation of the disease and may correlate with disease activity. If left untreated, ocular inflammation in rheumatoid arthritis can lead to permanent vision loss.</div></div><div><h3>Conclusions</h3><div>The diverse ocular inflammatory manifestations in RA patients may indicate either the disease's initial presentation or the status of extra-articular activity. A multidisciplinary approach that includes rheumatologists and ophthalmologists is essential to prevent sight-threatening complications.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501891"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144262871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Some aspects of body thermoregulation, environmental temperature and vascular hypothesis in systemic sclerosis patients","authors":"Francisco Javier Olmedo Garzón","doi":"10.1016/j.reuma.2025.501894","DOIUrl":"10.1016/j.reuma.2025.501894","url":null,"abstract":"<div><div>In line with vascular hypothesis of systemic sclerosis (SSc), it is proposed that visceral Raynaud's phenomenon (RP)/endothelial dysfunction causes severe oxygen supply/consumption imbalance in internal organs, leading to visceral ischemic failure in early SSc, especially with cold environmental temperature (Te) and severe RP. There would also be a decrease in body thermogenesis and a decrease in heat loss caused by chronic visceral ischemia and by systemic vasculopathy, respectively. At any given time, these disorders could produce low core temperature (Tc). Hence, SSc is proposed as a candidate cause of secondary hypothermia. It is suggested that SSc could be an adaptive response in cold Te to systemic endothelial damage with secondary chronic visceral ischemia/slow metabolism. This pathophysiological mechanism is proposed in early visceral failure, prognosis, SSc phenotype according to ethnicity, and other manifestations. The impact of Te and Tc on SSc warrants further investigations.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501894"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pósteres: P319-P510","authors":"","doi":"10.1016/S1699-258X(25)00148-2","DOIUrl":"10.1016/S1699-258X(25)00148-2","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 ","pages":"Pages S456-S640"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144702260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry","authors":"Clementina López-Medina ,&nbsp;Lucía Otero-Varela ,&nbsp;Fernando Sánchez-Alonso ,&nbsp;Vega Jovaní ,&nbsp;Lorena Expósito-Pérez ,&nbsp;Sheila Melchor-Díaz ,&nbsp;Yanira Pérez-Vera ,&nbsp;Paula Pretel-Ruiz ,&nbsp;Javier Manero ,&nbsp;Antonio Mera-Varela ,&nbsp;Lourdes Mateo ,&nbsp;Dolores Ruiz-Montesino ,&nbsp;José Andrés Lorenzo-Martín ,&nbsp;Teresa Pedraz-Penalva ,&nbsp;Isabel Castrejón","doi":"10.1016/j.reuma.2025.501872","DOIUrl":"10.1016/j.reuma.2025.501872","url":null,"abstract":"<div><h3>Introduction</h3><div>Ixekizumab (IXE) is a selective interleukin 17A (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Limited real-world data are available on its retention rate and effectiveness. The objective of this study was to assess the one-year retention rate of IXE in a real-world cohort of patients with axSpA and PsA and to identify potential predictive factors for drug retention.</div></div><div><h3>Method</h3><div>Prospective and observational study derived from BIOBADASER 3.0, a multicenter registry of advanced therapies including patients who have ever received IXE for PsA or axSpA. The one-year retention rate of the treatment in both diseases was evaluated using Kaplan–Meier curves and multivariable Cox regressions.</div></div><div><h3>Results</h3><div>A total of 335 patients ever exposed to IXE were included (PsA<!--> <!-->=<!--> <!-->250; axSpA<!--> <!-->=<!--> <!-->85). IXE was used as first-line treatment only in 5.3% of patients, and after TNFi in 94.7% of patients. In axSpA and PsA, drug survival at 12 months was 69.5% (95% CI 64.0–74.3), slightly higher in PsA (71.3% (95% CI 65.0–75.6)) versus axSpA (63.8% (95% CI 51.5–73.7)). The multivariable Cox regression models showed that female sex and longer disease duration were factors associated with IXE withdrawal in the whole population, while concomitant use of methotrexate reduced the risk of discontinuation.</div></div><div><h3>Conclusions</h3><div>In this real-world study, IXE showed an acceptable retention rate in patients with PsA and axSpA after one year of follow-up. Female sex and longer disease duration were associated with risk of withdrawal.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501872"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lupus nephritis in Mexican patients: Response to intensive therapy","authors":"Georgina Aguilera Barragán-Pickens ,&nbsp;David Herrera van-Oostdam ,&nbsp;Fedra Irazoque-Palazuelos ,&nbsp;Miguel Saavedra-Salinas ,&nbsp;Sergio Cerpa-Cruz ,&nbsp;Claudia Mendoza-Pinto ,&nbsp;Luis Valdez ,&nbsp;Enrique Cuevas Orta ,&nbsp;Eva Santillán-Guerrero ,&nbsp;Carlos Abud-Mendoza ,&nbsp;LUNPOS GROUP","doi":"10.1016/j.reuma.2025.501896","DOIUrl":"10.1016/j.reuma.2025.501896","url":null,"abstract":"<div><h3>Introduction</h3><div>lupus nephritis represents a challenge in treatment. In spite of intensive therapy, is common a sustained renal incomplete response.</div></div><div><h3>Objective</h3><div>To describe different responses to adequate/intensive treatment to lupus nephritis.</div></div><div><h3>Methods</h3><div>Observational retrospective study, including Mexican<!--> <!-->&gt;<!--> <!-->18 years old patients with lupus nephritis who visited tertiary rheumatology centers in several urban cities in Mexico. SLE was diagnosed according to 1997 ACR. The exclusion criteria were follow-up<!--> <!-->&lt;<!--> <!-->6 months and reduced GFR due to other comorbidities such as diabetes or other primary renal disease.</div></div><div><h3>Results</h3><div>We included 193 patients with a mean age of 34 years, 80% were women. Biopsy was available in 166 patients (86%): class IV in 42%, class III in 23%, the mean of activity and chronicity index were 6.4 and 2.6 respectively; class V represented 10.2%. The least frequent class was Class II (9%), and mixed classes (III or IV<!--> <!-->+<!--> <!-->V) accounted for 11%.</div><div>Cyclophosphamide (CYC) was used in 146 patients (76.6%), mycophenolate (MMF) in 144 and tacrolimus (TCR) in 28. In most cases, were used combination therapy.</div><div>Only 38 patients had a follow-up of less than 1 year; 16 (42%) had CR, 13 (34%) had NR, and 9 (23%) PR. 55% of patients with PR received a multitarget protocol, 75% of CR received the NIH protocol, and 61.5% of NR the NIH protocol.</div><div>Of patients followed up for more than a year (155), 35% had persistently inactive response, 24.5% were relapsing–remitting, 20% were chronically active, and 20% showed a mixed pattern.</div></div><div><h3>Conclusions</h3><div>Prevalence of persistent or intermittent activity patterns was high (64.5%). Most Mexican rheumatologists switched to more intensive treatment, adding a second or third drug.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 5","pages":"Article 501896"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144262870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: “Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: Data from the BIOBADAGUAY registry”","authors":"Sarah Aijaz ,&nbsp;Raveen Muzaffer","doi":"10.1016/j.reuma.2025.501871","DOIUrl":"10.1016/j.reuma.2025.501871","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 4","pages":"Article 501871"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}